Accretion Pharmaceuticals Posts Robust H1 FY27 Performance with PAT Surging 72.63% YoY
Accretion Pharmaceuticals Ltd · Press Release · 31 Oct 2026, 10:53 pm
Accretion Pharmaceuticals Posts Robust H1 FY27 Performance with PAT Surging 72.63% YoY Accretion Pharmaceuticals reported a 25.83% YoY increase in net revenue to ₹55.04 crore for H1 FY27 ending 30th Sep'26, driven by volume growth and an improved product mix. EBITDA grew 72.28% YoY to ₹12.37 crore, with EBITDA margin expanding 606 bps to 22.48%. PAT jumped 72.63% YoY to ₹8.20 crore, expanding PAT margin by 403 bps to 14.90%. Basic EPS rose to ₹7.38 from ₹4.61 in H1 FY26. Export revenue contribution nearly doubled to 18.15% from 9.16% YoY.
Original exchange filing (PDF)
More announcements from Accretion Pharmaceuticals Ltd
- Accretion Pharmaceuticals Limited has informed the Exchange about General Updates · 16 Nov 2026
- Accretion Pharmaceuticals Limited has informed the Exchange about Investor Presentation · 03 Nov 2026
- Accretion Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 02 Nov 2026
- Accretion Pharmaceuticals Limited has submitted to the Exchange, the unaudited financial results for the half year ended September 30, 2026. · 31 Oct 2026
- Accretion Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 31-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 31 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 31 Oct 2026
- Accretion Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has submitted the Exchange a copy of Srutinizers report. · 12 Oct 2026
- Accretion Pharmaceuticals Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company. · 11 Oct 2026
